TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
← catalyst calendarNCT07223203 · readout in 494 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
125estimated
Sites
48
Countries
Australia, Brazil, Canada +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-12 | actual | When the study began enrolling |
| Primary completion | 2027-12-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-06-12 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
- hATTR-PN
Interventions
- Drug: Nucresiran — also filed as ALN-TTRSC04
- Drug: Vutrisiran — also filed as AMVUTTRA, ALN-TTRSC02
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
measured Baseline and Month 9
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed